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Presence of Cross-Reactive Antibody Between Human Immunodeficiency Virus (HIV) and Platelet Glycoproteins in HIV-Related Immune Thrombocytopenic Pur pur a
By Ali Bettaieb, Patricia Fromont, Fawzia Louache, Eric Oksenhendler, William Vainchenker, Najib Dubdari, and Philippe Bierling
We previously reported the presence in platelet eluates of autoantibodies directed against epitopes of the platelet glycoprotein (GP)IIb/ llla complex in acquired immunodeficiency syndrome (AIDS)-free human immunodeficiency virus (HIV)-infected patients with immunologic thrombocytopenic purpura (ITP). We investigated whether HIV antibodies recognized platelet membrane antigens t o determine whether the virus might be directly or indirectly responsible for the thrombocytopenia in this context. Direct eluates of platelets from 25 patients with HIV-related ITP contained IgG reacting with HIV-GP160/120 and also, in 45% of patients, detectable antiplatelet antibodies, immunochemically characterized as anti-GPllb and/or anti-GPllla in 5 patients. Furthermore, serum HIV-GP16OI 120 antibodies could be absorbed on and eluted from platelets from normal non-HIV-infected healthy blood donors (indirect eluates). In contrast, GP1601120 antibodies present in the serum of nonthrombocytopenic HIVinfected patients were not absorbable on normal platelets in most patients, suggesting a pathogenic role in HIV-related DIOPATHIC thrombocytopenic purpura (ITP) is a fre-I quent hematologic disorder characterized by immunologic platelet destruction. ITP most often results from the presence of platelet autoantibodies directed mainly against epitopes localized on the glycoprotein (GP)IIb/IIIa com~l e x . l -~ A syndrome similar to ITP frequently occurs in HIV-infected patients regardless of the risk group to which they belong, eg, homosexual intravenous drug a b u s e r~,~J~ and hemophiliacs.11J2 Immunologically mediated platelet destruction has been clearly demonstrated in such patients,13 but the precise mechanism of the thrombocytopenia has not yet been established. Two main hypotheses have been advanced. The first hypothesis implicates nonspecific deposition of circulating immune complexes on the platelet surface with subsequent clearance of the opsonized platelets.' This hypothesis is supported by the presence of anti-HIV antibodies and the absence of detectable HIV antigens on the platelet surface.14 Certain evidence indicates that anti-F(ab')* antibodies directed against ITP. We performed detailed studies of a patient with the highest titer of both HIV-GPIGO/ 120 and GPllb/llla antibodies in direct and indirect platelet eluates. No antibody binding t o GPllb/ Illa-deficient Glanzmann thrombasthenic platelets was detected. Furthermore, bindinglelution experiments conducted with insoluble recombinant GP160 (expressed in baculovirus) and purified platelet GPllb/llla demonstrated that the patient's IgG bound specifically, through the F(ab')z portion, t o a common epitope of HIV-GPIGO/ 120 and platelet GPllb/Illa. This common epitope was present on a recombinant GP160 expressed in baculovirus but absent from another recombinant GP160 expressed in vaccinia virus, suggesting that the cross-reactivity is dependent on the glycosylation or conformational structure of the GP. We conclude that molecular mimicry between HIV-GPlGO/ 120 and platelet GPllb/llla may explain at least some cases of ITP in AIDS-free HIV-infected patients. Q 1992 by The American Society of Hematology.
HIV antibodies (antiidiotypic antibodies) might play a role in the formation of such immune c0mp1exes.l~ The second hypothesis, supported by the findings of two independent teams of investigators, is based on the presence of specific platelet antibodies. Thus, von dem Borne et a P J 7 reported the presence of platelet autoantibodies in most HIVinfected patients with or without thrombocytopenia and concluded that the nature of these autoantibodies was not different from that of the autoantibodies observed in classic ITP. We demonstrated that ITP in HIV-infected AIDSfree patients results, at least in some patients, from the presence of platelet autoantibodies directed mainly against epitopes localized on platelet GPIIb/IIIa. 18 To reconcile the two hypotheses, we investigated the possible involvement of molecular mimicry between HIV and platelet antigens. Our results, showing cross-reactivity of HIV antibodies with platelet GPIIb/IIIa, could explain some cases of ITP in HIV-infected patients.
PATIENTS AND METHODS
Blood samples were obtained from HIV-infected patients with (n = 28) or without (n = 11) ITP. The presence of HIV antibodies was demonstrated by enzyme-linked immunosorbent assay (ELISA) and Western blotting analysis in the serum of all subjects. The patients with ITP belonged to the following risk groups: drug addicts (n = 18), homosexual men (n = 7), and transfusion recipients (n = 3). We previously reported immunohematologic findings in 22 of these 28 patients, including the three whose platelet eluates precipitated GPIIb/IIIa.18 Among the nonthrombocytopenic patients, five were homosexual men, four were drug addicts, and two were female sexual partners of seropositive men. The patients with ITP satisfied the following diagnostic criteria: isolated thrombocytopenia with a platelet count less than 50 x 109/L, an increased number of megakaryocytes in an otherwise normal bone marrow (BM) aspirate, absence of Centers Platelets were harvested from the patients, healthy blood donors, and patients with Glanzmann's thrombasthenia (GT) by differential centrifugation of whole blood collected onto EDTA and/or acid-citrate-dextrose (ACD) A anticoagulant.
Contamination with WBC was < 1/1,OOO platelets.
Platelet autoantibody determination. Platelet-associated IgG (PAIgG) was detected according to the method described by von dem Borne et Samples (sera, eluates or F(ab')z fragments) were tested for antiplatelet membqne activity by means of an indirect immunofluorescence test (PIIFT) on paraformaldehydetreated plateletsz2 with fluorescein-conjugated F(ab'), antihuman (y) IgG or antihuman light chains (Dakopatts, Copenhagen, Denmark).
In some cases, sera and eluates were also studied in immunoprecipitation experiments. Platelets 1 x lo9 were surface-labeled with lzIodine using the lactoperoxidase catalyzed meth0d.2~ The platelets were subsequently solubilized in 1 mL buffer A [containing Tris-HC1 20 mmol/L NaCl 150 mmol/L (Tris-buffered saline-TBS), Triton X-100 1%, EDTA 5 mmol/L, phenylmethylsulfonyl fluoride (PMSF) 2 mmol/L, and 0.5 pg/mL leupeptin] for 30 minutes at 4"C, and the lysate was centrifuged for 30 minutes at 17,600g at 4°C. Fifty microliters of lysate were then incubated overnight at 4°C with 50 pL serum, 100 KL eluate, or 10 pL purified monoclonal antibody (MoAb). Two hundred microliters of a 10% suspension of protein A-Sepharose (Pharmacia, Paris, France) were added to the lysate and incubated for 1 hour at 4°C. The beads were then washed five times with buffer A, two times with buffer A supplemented with 0.2 mol/L NaCI, and two times with buffer A supplemented with 0.35 mol/L NaCI. Fifty microliters of 2% sodium dodecyl sulfate (SDS) and 5% P-mercaptoethanol were added to each pellet and, after boilifig for 5 minutes, the solutions were analyzed in a 7.5% sodium dodecyl sulfate (SDS)-polyacrylamide gel according to the method of LaemmLx Gels were then fixed, dried, and autoradiographed.
Ether elution of PAIgG was performed according to the method of Helmerhorst et
The direct eluates were then tested for antiplatelet and anti-HIV activity in different techniques in comparison with the last platelet washing fluid to detect possible contamination of the eluates by serum. Results were interpreted only if the last platelet washing sample was negative. Negative controls included direct eluates of platelets from normal individuals and HIV-negative patients with ITP.
HIV antibodies were detected using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Abbott Laboratories, Paris, France) and by Western blot immunoassay (Dupont De Nemours, Les Ulis, or Diagnostics Pasteur, Marnes-La-Coquette, France). The ELISA kit contained mainly GP41 and GP24 recombinant-HIV proteins, with small amounts of GP160/120 and GP55 of HIVl and GP41 of HIV2. The ELISA was considered positive if the ratio of sample absorbance to positive control absorbance was greater than or equal to the calculated optical density (OD) cutoff value (the cutoff value was calculated according to the manufacturer's recommendations using the negative and positive controls included in the commercial kit). In the HIVl Western blot assay, eluates (diluted 1:40) were incubated with the test strips for 2 hours at room Plateletpreparation.
Platelet eluates. H W antibody determination.
temperature and the bands were disclosed by an alkaline phosphatase-conjugated goat anti-human serum (Diagnostics Pasteur) or by a series of reactions with goat antihuman IgG conjugated with biotin, avidin conjugated with horseradish peroxidase (HRP), and the HRP substrate 4-chloro-1-naphtol (Dupont). The result was considered positive in these experiments when at least one band was visualized.
HIV antibodies from patient Bou platelet direct eluates were detected by indirect immunofluorescence on methanol-permeabilized (1 minute at 22°C) cytocentrifuged U937 and CEM cell lines infected by the HTLV-IIIB and Bru-HIV isolates, respectively. HIV antigens were sought on the patient's platelets by immunoblotting,26 immunoprecipitation,'* and the indirect immunofluorescence procedure,22 using the following HIV MoAbs: anti-p24, anti-pl7, and anti-Gpl2O (provided by Dr R.M. Vazeux, Institut Pasteur, Paris, France). Two additional antibodies were used in the immunofluorescence technique, one directed against p25, p34, p55, and p65, (Genzyme, Boston, MA) and the second recognizing GP160/120 (Biosoft, Paris, France).
IgG was purified from patient Bou serum by means of the staphylococcal protein A-sepharose C U B technique (Pharmacia, Paris, France), as described by Ey et a1J7 Five milligrams IgG was then digested by 0.1 mg pepsin at pH 4.5 for 18 hours at 37°C. The F(ab')z fragments were subsequently dialyzed against phosphate-buffered saline (PBS) and purified on an insoluble Protein A-column. Samples were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) to detect the possible presence of intact IgG in the F(ab')z preparations. The F(ab')2 fragments were used in binding and elution experiments only if intact IgG was undetectable.
Platelet binding and elution qerimentspe8ormed with patient sera.
Washed platelets ( lo9) harvested from healthy blood group 0 donors or GT patients were suspended in 500 pL PBS containing 3 mmol/L EDTA and 0.25% bovine serum albumin (BSA) and then incubated with 500 pL patient serum or plasma for 2 hours at toom temperature. The mixture was subsequently washed in 20 mL of the same buffer four times with repeated centrifugation. The platelets were resuspended in 500 pL buffer, and 1 mL diethyl ether was added. The samples were then shaken for 2 minutes, incubated for 30 minutes at 37"C, and spun for 10 minutes at 3,000 g. The indirect eluates (aqueous solution) were tested in parallel with the last washing fluid for antiplatelet and anti-HIV activity. Results were interpreted only if the last platelet washing sample was negative.
Binding and elution experiments peflormed with eluates, sera, and F(ab')2 fragments on recombirtant GP160 and purified platelet GPZZblZZZa. Two recombinant GP160s (rGP160) of the HIVl envelope (rGP160-1, rGP160-2), supplied by Drs M. Girard and M. Kaczorek (Pasteur Merieux, Val de Reuil, France) and by Repligen (Cambridge, MA), respectively were studied. rGP160-1 is secreted into the culture medium of baby hamster kidney (BHK 21) cells infected by the recombinant vaccinia virus W 1163.28
Amino acid sequencing has shown that rGP160-1 lacks 22 amino acids at position 696 to 717.28 rGP160-2 (derived from the IIIb isolate of HIV1) is expressed as a full-length protein in insect cells by using a baculovirus expression vector and is neither processed nor s e~r e t e d .~~,~~ Four hundred micrograms of the rGpl60 was coupled to 0.5 mL Atfi-gel 10 according to the manufacturer's directives (BioRad, Paris, France).
Platelet GPIIb/IIIa was purified from human platelets as described by Fitzgerald et with modifications. The platelet lysate was loaded onto a Concanavalin A-ultrogel column. 
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Germain en Laye, France), and then dialyzed against TBS containing 0.1% Triton-X 100. Further purification was performed with insoluble anti-GPllla MoAb (SZ21) (Immunotech, Marseille, France) coupled to a column of Affi-gel 10 (1 mg antibodyll mL Affi-gel 10). GPIlblllla complex was eluted from the column with 0.1 mollL glycin, 0.1 mollL NaCI, and 0.1% Triton X-100, pH 2.8, and the eluted fraction was immediately neutralized with 1 mollL Tris. The purified GPllblllla was greater than 90% homogeneous as analyzed by SDS-PAGE. The only slight contaminant observed was the fibrinogen that was probably copurified with the GPIlbl Illa. In addition. in an ELISA, the GPllblllla preparation failed to react with HIA class I, CD42b, CDw49b. and CD62 MoAbs demonstrating that this material was free of the other major platelet GPs. Five hundred micrograms of purified GPllb/llla was coupled to 0.5 mL Affi-gel 10 according to the manufacturer's directives (BioRad, Paris, France).
Absorption experiments with eluates, sera or F(ab')z fragments were performed using Affi-gel 10 coupled to ffiP160 or to purified GPllblllla. After several washes, absorbed materials were eluted by addition of an aqueous buffer containing 150 mmollL H>P04/ 100 mmol/L NaCI/I.5% BSA, pH 2.8, for 10 minutes at 4°C. The acidified suspension was centrifuged and then neutralized with 1 mol/L Tris. Eluted materials were tested for antiplatelet and anti-HIV activity in comparison with the last GP160 or GPllblllla Affi-gel column washing samples. Results were interpreted only if the last platelet washing sample was negative. three reported in our previous work,l* precipitated platelet GPIIb/lIIa (partially illustrated in Fig 3) . In contrast, a weak increase in PAIgG was observed in only 2 of the 11 nonthrombocytopenic patients (18%) and was never eluable. Likewise, sera of 25 of the 28 thrombocytopenic but only 3 of the 11 nonthrombocytopenic patients were positive in the PIIFT.
RESULTS

Platelet autoantibody determination.
Presence of H N antibodies on platelets @m HN-infected thmmhytopenic patients. Direct platelet eluates from HIV-infected thrombocytopenic (n = 25) and nonthrombocytopenic patients (n = 11) were tested using ELISA and Western blot procedures for the presence of HIV, antibodies (Fig 1) . In the ELISA, 21 of the 25 eluates (84%) from thrombocytopenic patients were positive, whereas only 3 of the 11 eluates (27%) from nonthrombocytopenic patients were weakly positive. use only.
For
Binding of serum HIV antibodies to normal platelets. Because HIV antibodies were present but HIV antigens were not detectable on the membrane of platelets from the HIV-infected ITP patients, we determined whether HIV antibodies could bind to platelets from uninfected healthy blood donors. Indirect platelet eluates were thus obtained by ether elution after incubation of patient sera with normal platelets. As shown in Fig 1, all 14 indirect platelet eluates obtained with serum from HIV-infected ITP patients were positive in the HIV-Western blot immunoassay. All of these eluates recognized GP160/120, and two also recognized other viral proteins, ie, p17, p24, p31, p53, p68. In the HIV-ELISA, 13 of these eluates were negative, whereas one (the sample showing antiplatelet activity in the PIIFT, ie, patient Bou [described below]) was strongly positive (four times the cutoff value). In contrast, only two of eight eluates obtained with serum from HIV-infected non-ITP patients were weakly positive in the Western blot immunoassay (recognizing GP160/120), whereas all were negative in the HIV-ELISA and the PIIFT. The discrepancies between the results obtained in the HIV Western blot immunoassay and the HIV-ELISA with both the indirect and direct eluates may have been due to the presence of only trace amoutlts of GP160/120 in the ELISA kit, since GP160/120 antibodies were predominant in the eluates. To determine whether this ability of HIV antibodies to bind to platelets from HIV-negative patients was specific (ie, due to the presence of cross-reactive antigens between platelets and virus) or nonspecific (ie, Fc binding), we focused our study on patient Bou, who showed the highest serum titer of antiplatelet and anti-HIV activities able to bind to normal platelets.
The PAIgG eluted from patient (auto) and normal (allo) platelets preincubated with patient serum were strongly reactive in the PIIFT with platelets from healthy blood group 0 donors (Table 1 ). In contrast, they did not recognize ABO-compatible platelets from two GT patients with no detectable GPIIb/IIIa in immunochemical analysis, strongly suggesting anti-GPIIb and/or anti-GPIIIa specificity of the platelet antibody. Furthermore, the direct Bou platelet eluate immunoprecipitated a band of 97 Kd characterized as GPIIIa (see Fig 3) . As we have reported for other patients,18 the sera of the patients in this study could not Characterization of PAIgGfrompatient Bou.
precipitate platelet GPIIb/IIIa. The direct and indirect eluates also contained HIV antibodies (described above) detectable in the ELISA and HIV-Western blot immunoassay (Table 1, Fig 2) . In this latter assay, only GP160/120 antibodies were detectable (Fig 1, strips 2 and 8 , Table 1 ). To determine if two distinct antibodies were present in these eluates, we performed absorption/elution experiments with ABO-compatible platelets from two GT patients. Neither the anti-HIV nor antiplatelet activity present in the patients' sera or in the direct or indirect eluates were able to bind to these GT platelets. These results, contrasting with those obtained in binding/elution experiments with normal healthy blood-donor platelets (described above), suggested that both patient Bou HIV and platelet antibodies bound to GPIIb/IIIa (Fig 2 and Table 1 ).
The presence of cross-reactive antibody between platelet GPIIb/IIIa and HIV GP160 in patient Bou serum and the anti-GPIIb/IIIa specificity of Bou platelet antibody was confirmed by binding/elution experiments with patient Bou serum on insoluble purified GPIIb/IIIa. As shown in Table   1 , the antibodies eluted from purified immobilized GPIIb/ IIIa recognized healthy blood-donor ABO-compatible platelets in the PIIFT and HIV-Gpl60 in the HIV-Western blot immunoassay. The anti-GPIIb/IIIa specificity of the platelet antibody was confimed by an immunoprecipitation procedure, because, when incubated with '"1-labeled platelets, the eluate obtained from purified immobilized GPIIb/ IIIa incubated with patient serum (as well as with direct platelet eluate) precipitated a band of 97 Kd in reducing conditions which comigrated with the GPIIIa precipitated by an PLAl antibody or a GPIIIa MoAb (SZ21) (Fig 3) . Controls of these absorption-elution experiments included serum of a nonthrombocytopenic HIV-infected patient (that did not recognize the immobilized GPIIb/IIIa) and polyclonal GPIIb/IIIa antibodies from an HIV-negative GT patientz6 (The eluate obtained from the immobilized GPIIb/IIIa column after incubation with this latter serum contained only GPIIb/IIfa antibody).
To determine whether binding of the cross-reactive platelet antibody to normal platelets or to purified GPIIb/ IIIa was specific, the same experiments were performed with the F(ab')z fragment of purified serum Bou IgG. As shown in Fig 2, similar results to those observed with patient serum were obtained with this material. Thus, both the platelet and HIV GP160 antibody activities present in patient Bou F(ab');! fragments were capable of binding to ether-eluates from GT platelets preincubated with the serum (3).
Flab'), fragments obtained from purified patient Bou serum IgG (4); ether-eluates from normal platelets preincubated with the F(ab'), fragments (5). and ether-eluates from GT platelets proincubated with the F(ab'), fragments (6) . The antiplatelet activity in each sample was present in the bottom and was graded as negative (-) , or positive (+ to + + +) in comparison with results obtained using negative control (serum from a nontransfused healthy male blood group AB donor), and positive control (pool of sera from multitransfused immunized patients).
normal healthy blooddonor platelets but not to GT platelets. Likewisc, binding/elution experiments with this material on insoluble purified GPIIb/IIIa demonstrated that GPIIb/IIIa antibody was entirely absorbed on the column and that the GPIIb/IIIa column cluate contained HIV GP160 antibody (data not shown). Furthermore, in these experiments, F(ab')z binding could be demonstrated only with an anti-light chain but not with an antiglobulin directed against the Fc portion of the y chain, ruling out binding by residual IgG contaminating the F(ab')z prcparation. Overall, these results dcmonstrated thc prescncc in patient Bou of GP160/120 antibodies able to bind spccifically to platelet GPIIb/IIIa.
Binding of the cross-reactive antibody to r-GPI60 of the HIV-I envelope GP. To characterize the cross-rcactive epitope between HIV-GP160/120 and platelet GPIIb/IIIa. several experiments were conducted (Table 2) . Direct Bou platelct eluate did not recognize the ccll membranc of HIV-I-infcctcd ccll lines (U937-HTLVIII and CEM-BN), whereas intracytoplasmic staining was observed when infected cells were permeabilized with methanol and Triton X-100, suggesting that the eluate containcd HIV antibodies probably directcd against the native immature GP160. Binding and elution cxperiments were performed with paticnt Bou platclet cluatcs on the two immobilizcd r-GP160s of thc HIV envelope. Nonabsorbed and clutcd materials from the column were tested for anti-HIV and antiplatelet activities. As shown in Table 2 , neither thc antiplatelet nor anti-HIV activities present in the Bou eluatc bound to r-GP160-1, whereas they bound almost completely to r-GP160-2. The same results were obtained with thc patient Bou serum F(ab')z fragments. These results suggest either that the cross-reactive epitope rccognizcd was located on the deleted portion of r-GPI60-I (prcsent on r-GP160-2) or that it is dependent on the glycosylation or conformational structure of thc GP. PIIFT, platelet indirect immunofluorescence test on normal platelets. Platelet membrane fluorescence was graded as negative (-) , weakly positive (+), or positive (+ to +++) in comparison with results obtained using negative control (serum from a nontransfused healthy male blood group AB donor), and a positive control (pool of sera from multitransfused immunized patients). Direct eluate, antibodies eluted from patient Bou's own platelets; indirect eluate, antibodies eluted from normal platelets preincubated with patient Bou serum.
*r-GPlGO (1) and (2), two different recombinant GP160 of the HlVl envelope (described in the Materials and Methods section).
Karpatkin et a1 suggested that both autoantibody fixation and nonspecific immune complex deposition may be responsible for the thr~mbocytopenia.~,~~,~~ The present findings concerning 28 HIV-infected ITP patients confirm pur previous results.ls IgG with antiplatelet activity was observed in the serum of 89% of the patients, PAIgG levels were increased in 80%, and 9 of 20 direct platelet eluates contained platelet antibodies sometimes immunochemically characterized as anti-GPIIb/IIIa. In addition, we noted that in one of these patients (patient Bou), serum antiplatelet IgG specifically bound to normal platelets and purified immobilized GpIIb/IIIa through the F(ab')2 fragments. These results argue for an autoimmune cause of the thrombocytopenia.
We also observed HIV antibodies (mainly anti-GP160/ 120) in the direct eluates of the patients' platelets as previously reported.14,33 Apparently because HIV antibodies bind in vivo to the platelet membrane and not because a granule-incorporated plasma proteins are extracted,34 since GP160/120 antibodies were strongly predominant and were absorbed by or eluted from normal platelets but not from GT platelets. This binding was not explained by the presence of HIV antigens on the platelet membrane because viral antigens were not detectable in various immunologic tests and especially because the anti-HIV activity also bound to platelets from HIV-negative subjects. The absence of viral antigens or proviral DNA on HIV-ITP platelet extracts has been reported by other investigat~rs.'~ Furthermore, binding of HIV antibodies to the platelet surface was specific in the case of patient Bou and occurred through the F(ab')2 portion. Indirect evidence for the responsibility of this anti-HIV activity in immune platelet destruction is the finding that all direct and indirect platelet eluates from thrombocytopenic patients, but only a few of those obtained from nonthrombocytopenic patients, contained anti-GP160/ 120 antibodies.
The specific binding of both anti-HIV and antiplatelet activities to normal platelets and purified GPIIb/IIIa suggested the presence of an antibody that recognizes both HIV and platelet antigens. Shared antigenicity between an infectious agent and normal tissue as a mechanism of host damage has been demonstrated in parasitic, bacteriaP3' and, more recently, viral ~y s t e m s .~~-~l To test this hypothesis, we focused our study on patient Bou, who showed the highest titer of antiplatelet (anti-GPIIb/IIIa) and anti-HIV (anti-GP160/120) activities that specifically bound to normal platelets and purified GPIIb/IIIa. Results of the absorption-elution experiments on purified immobilized GPIIb/IIIa, which bound both patient Bou GPIIb/IIIa and HIV GP160 antibody, as well as the absence of binding of either activity to platelets from GT patients clearly demonstrated the presence in the serum or eluates of a single antibody with both activities. This antibody recognized only the native immature GP160 in HIV-infected cell lines. To confirm cross-reactivity, we performed cross-absorption experiments with two r-GP160s and direct and indirect Bou eluates, as well as serum F(ab')2 fragments. The cross-reactive antibody could be absorbed on r-GP160-2 (expressed in baculovirus-infected insect cells) but not on r-GP160-1 (expressed in vaccinia virus-infected BHK 21 cells). Then, we believe, the absence of recognition of r-GP160-1 would result from abnormal glycosylation leading to conformational changes and rendering some epitopes inaccessible.
Therefore, we clearly demonstrated in patient Bou the presence of a platelet-bindable antibody that specifically recognizes an epitope (not precisely identified) shared by HIV GP160/120 and platelet GPIIb/IIIa, suggesting that homologies exist between the two GPs. Perhaps only small numbers of HIV-infected patients develop such antibodies at a titer sufficient to lead to platelet destruction. Alternatively, HIV antibodies may also occasionally bind to undetectable viral antigens on the platelet membrane, because we33 and other investigator^^^ have demonstrated the presence of HIV transcripts and, occasionally, HIV proteins in megakaryocytes from HIV-infected thrombocytopenic patients. However, the presence of both GP160 and GPIIb/ IIIa antibodies in at least 5 of the 20 direct platelet eluates studied argues for the frequent responsibility of crossreactive antibodies in the immune platelet destruction observed in HIV-infected patients. Finally, if the hypothesis of cross-reactivity is confirmed, the antigenic structure involved will be of importance because it will have to be taken into account in treatment of such patients and in production of vaccines based on HIV envelope components. 
